Vivo Infusion, an ambulatory infusion provider backed by InTandem Capital, acquired Infusion Associates for between $180 million and $220 million, sources familiar tell Axios.
Why it matters: Similar to clinical trial site management, the fragmented infusion market has been a bright spot in health care investing for PE.
